Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Federal Trade Commission
Chubb
McKinsey
Fuji
Fish and Richardson
Merck
Daiichi Sankyo
Boehringer Ingelheim

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR JARDIANCE

« Back to Dashboard

Clinical Trials for Jardiance

Trial ID Title Status Sponsor Phase Summary
NCT01001962 Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics Not yet recruiting Aristotle University Of Thessaloniki Phase 4 Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects receiving EMPAGLIFLOZIN 3. Reduction in the total cardiovascular risk 4. 3 years morbidity and mortality rates 5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving EMPAGLIFLOZIN
NCT02367131 Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus Active, not recruiting Eli Lilly and Company N/A Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
NCT02367131 Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus Active, not recruiting Boehringer Ingelheim N/A Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
NCT02401880 Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology Completed Profil Institut für Stoffwechselforschung GmbH Phase 4 The primary aim of this exploratory mechanistic study is to investigate the effects of Empagliflozin and Linagliptin on alpha- and beta cell physiology in T2DM patients. This study aims to evaluate the effect of the DPP-IV inhibitor linagliptin (as compared to placebo) in addition to the SGLT-2 inhibitor empagliflozin on pancreatic alpha and beta cell function, as well as several markers of metabolic control.
NCT02471963 Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function Completed University of Erlangen-Nürnberg Medical School Phase 3 Empagliflozin may lead to improved vascular and endothelial function in the macro- (pulse wave reflection) and microcirculation (retinal circulation) and improve cardiovascular risk factors, imparticular by effectively controlling hyperglycemia, arterial hypertension and obesity.
NCT02489942 Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus Recruiting Eli Lilly and Company N/A Study to investigate the safety and efficacy of long-term daily use of JARDIANCE® Tablets in Japanese patients with type 2 diabetes mellitus
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Jardiance

Condition Name

Condition Name for Jardiance
Intervention Trials
Diabetes Mellitus, Type 2 6
Type 2 Diabetes Mellitus 4
Type2 Diabetes 3
Type 2 Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Jardiance
Intervention Trials
Diabetes Mellitus 22
Diabetes Mellitus, Type 2 22
Heart Failure 4
Non-alcoholic Fatty Liver Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Jardiance

Trials by Country

Trials by Country for Jardiance
Location Trials
Germany 7
Japan 3
Switzerland 3
Korea, Republic of 3
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Jardiance

Clinical Trial Phase

Clinical Trial Phase for Jardiance
Clinical Trial Phase Trials
Phase 4 16
Phase 3 3
Phase 2/Phase 3 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Jardiance
Clinical Trial Phase Trials
Recruiting 13
Not yet recruiting 11
Completed 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Jardiance

Sponsor Name

Sponsor Name for Jardiance
Sponsor Trials
Boehringer Ingelheim 9
Eli Lilly and Company 4
Profil Institut für Stoffwechselforschung GmbH 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Jardiance
Sponsor Trials
Other 40
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Army
Cerilliant
Covington
Argus Health
McKinsey
Daiichi Sankyo
Express Scripts
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.